The OSUCCC Clinical Trials Office (CTO), rated """"""""Excellent to Outstanding"""""""" in the 1999 review, supports the centralized administration of protocol conduct, development, review, implementation, monitoring, regulatory compliance, and quality assurance. The CTO is a shared resource of the OSUCCC that provides centralized management of all clinical trials conducted within the OSUCCC. The mission of the CTO is to foster a supportive environment conducive to the conduct of clinical trials by OSUCCC members and to provide a centralized resource to OSUCCC investigators for protocol administration, tracking and monitoring, data management, regulatory guidance, and financial management necessary for the successful conduct of clinical trials in a methodologically-sound, expedient, and cost-effective manner. The CTO came under the medical leadership o! John Byrd, M.D., and administrative leadership of Susan Ebert, R.D., M.S., in 2001. Since that time, the clinical research staff of Radiation Oncology, Stem Cell Transplant Program, Head &Neck Oncology, The Cancer and Leukemia Group B (CALGB), The AIDS-Related Malignancy Consortium (AMC), The CLL Research Consortium, and The NCI/CTEP Phase I Program have been consolidated within the CTO. This effort of consolidation as well as new clinical research faculty recruits and a consequent 232% increase in accrual to investigator-initiated studies (580 in 1999 and 1,926 in 2003) has resulted in the current CTO staffing of 38.5 FTE for its 224 open protocols, including 12 funded through NCI R21 QuickTrial grants. With recent acquisition of 7,000 nsf of space for the CTO, plans are to consolidate 20 remaining research staff conducting select cooperative group trials (ACOSOG, NSABP, and GOG) over the next two years in order to finalize centralization of all cancer clinical research activities. The CTO has reinforced infrastructure in the past several years with the creation of two new position titles, Regulatory Coordinator and Financial Manager. In addition, management infrastructure was improved with the creation of two new supervisory roles, the Clinical Research Manager (who manages all research nurses) and Data Management Supervisor (who manages research associates). A new web-based Cancer Research Information System (CRIS) has been developed for use by the CTO staff that vastly improves tracking of all research activities and provides the OSUCCC leadership and membership with the tools to monitor progress;2627 patients were entered on trials and registered into the CTO CRIS database during the most recent 12-month period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743469
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$353,508
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Nyankima, A Gloria; Rojas, Juan D; Cianciolo, Rachel et al. (2018) In Vivo Assessment of the Potential for Renal Bio-Effects from the Vaporization of Perfluorocarbon Phase-Change Contrast Agents. Ultrasound Med Biol 44:368-376

Showing the most recent 10 out of 2602 publications